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responses to all 23 questions. The vast majority of special-
ists, of whom >90% were endocrinologists, had used Se, 
and around 25% of them often or always. Let’s look into 
the thyroid phenotypes investigated  [9] .
 Chronic Autoimmune Thyroiditis in Euthyroid 
Individuals 
 While 3 out of 4 respondents (72%) thought that there 
was evidence supporting Se use, 79% prescribed it some-
times, often, or always. Half of those who prescribed Se 
(49%) did it prophylactically to prevent serum TSH in-
crease (49%) or to decrease thyroid antibody levels (39%). 
However, trials among individuals not receiving levothy-
roxine (LT 4 ) have not reported these effects  [10] . 59% of 
the respondents advocated use of >100 μg Se daily, with-
out having knowledge of the pretherapy Se levels. Impor-
tantly, the scientific societies do not recommend Se sup-
plementation for this indication.
 Hypothyroidism, with or without TPOAb 
 In case of subclinical hypothyroidism and positive 
TPOAb, 2 out of 3 respondents would (sometimes, often, 
or always) suggest use of Se. In case of negative TPOAb 
this propensity would decrease to 1 in 3 respondents. The 
 Selenium (Se) deficiency has been associated with a 
number of diseases  [1] , including thyroid diseases such as 
goiter, hypothyroidism, and autoimmune thyroiditis  [2] . 
Se is an essential micronutrient that is incorporated into 
biologically active selenoproteins as the amino acid sele-
nocysteine  [3] . Among the most important are the iodo-
thyronine deiodinases that are directly involved in thyroid 
hormone metabolism  [3] . In healthy euthyroid individu-
als with marginal Se deficiency, Se supplementation has 
only minute, and clinically insignificant, effects on thy-
roid function  [4] . However, Se levels have been found to 
be inversely correlated with thyroid size  [5] . Furthermore, 
Se supplementation has been shown to decrease thyroid 
peroxidase antibodies (TPOAb) in autoimmune thyroid-
itis  [6, 7] . Accepting that chronic autoimmune thyroid 
diseases are multifactorial diseases, and that environmen-
tal triggers are key components in their etiology  [8] , it is 
no surprise that Se deficiency has come into focus. It could 
be speculated that the above constitutes, in part, the inspi-
ration for the massive use of Se, as revealed by an Italian 
questionnaire study focusing on the therapeutic use of Se 
in some well-characterized clinical situations  [9] . Despite 
the inherent reservations in using such a questionnaire 
study, the survey seems to show that a number of special-
ists have adopted routine Se therapy in disease entities 
where the evidence is, to put it mildly, questionable. 
 From a web-based survey of 1,888 Associazione Medi-
ci Endocrinologi (AME) members, 778 (41%) provided 
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latter figures were also valid for hypothyroid individuals 
already on LT 4 . Systematic reviews and meta-analyses 
have shown that TPOAb levels, which we consider a sur-
rogate activity marker, do decrease  [6, 7] in patients re-
ceiving LT 4 treatment. However, this practice is not en-
dorsed by any specialist society.
 Chronic Autoimmune Thyroiditis and Pregnancy in 
Euthyroid Individuals 
 Of the respondents who were proponents of Se use 
(40%), their aim was to (in descending order): prevent 
development of hypothyroidism (40%), reduce TPOAb 
levels (31%), or prevent postpartum thyroiditis (25%). Of 
the respondents who would suggest giving >100 μg Se 
daily (70%), 10% would use a dose >200 μg daily. The lat-
ter could have deleterious effects when pretherapy Se lev-
els are not known. Again, it is important to recognize that 
guidelines do not support this practice  [11] .
 Graves’ Ophthalmopathy 
 Given a case of a 42-year-old female with Graves’ dis-
ease and no ophthalmopathy, 20% of the respondents 
would suggest adding Se to antithyroid drug therapy. In 
case she developed mild GO, 1 in 4 respondents would 
add Se, and 50% of respondents would continue with Se 
also after remission of her Graves’ hyperthyroidism. 
Based on a single study by Marcocci et al.  [12] , which 
showed significantly improved quality of life, reduced eye 
involvement, and improved clinical activity score in the 
Se group, the European Thyroid Association suggests a 
6-month trial of Se in patients with mild GO  [13] . While 
some have found lower Se levels in Graves’ hyperthyroid-
ism with GO compared to without GO, others have not 
found an association between Se status and GO severity 
or activity  [14] . Confirmation and clarification of poten-
tial mechanisms for the effect in GO are therefore eagerly 
awaited.
 We are probably not the only ones confronted with the 
statement: ‘You may be right about a questionable effi-
cacy, but Se is then at least harmless.’ However, this is 
incorrect. There is much to suggest a U-shaped link with 
Se status; whereas supplementation may benefit people 
with low Se status, those with adequate-to-high status 
might be affected adversely and should not take supple-
ments  [1] . This, as a minimum, requires that basal levels 
in a given individual or population is known before ad-
vocating Se supplementation. Recent studies have in-
creasingly been focused on the potential side effects of Se, 
also when levels are within the ones reached by Se supple-
mentation as low as 100–200 μg  [15] . 
 The current evidence of a clinically meaningful, cost-
effective, durable, and safe implementation of Se supple-
mentation is very sparse. Current use, at least in Italy,
is not based on evidence and may well be harmful. The 
article by Negro et al.  [9] is timely, important, and fright-
ening. It teaches us an important message. Not imple-
menting evidence-based medicine, needless to say, is un-
acceptable. However, implementing therapy, which po-
tentially may turn out to be harmful, and for which there 
is no evidence is, in our view, much worse. Ongoing pro-
spective, randomized, long-term studies, in both Graves’ 
disease  [16] and chronic autoimmune thyroiditis  [17] , 
will provide some answers concerning the value of sup-
plemental Se to antithyroid drugs and LT 4 , respectively. 
Until the data from these studies have been properly ana-
lyzed, and to avoid the risks of medical reversal  [18] , use 
of Se supplementation should be restricted to indications 
for which there is evidence, namely the correction of Se 
deficiency  [1] . Also, should indications for Se supplemen-
tation emerge, much work remains in order to define sub-
populations who will benefit the most, the type and dose 
of Se preparation, and length of therapy.
 From the data provided by Negro et al.  [9] , and given 
that they are truly representative of what Italian patients 
are advised to take, a number of pertinent questions arise. 
How have specialists in thyroid diseases come to these 
recommendations? Who has the responsibility for imple-
menting therapy that is not endorsed by any relevant au-
thority? Who has the responsibility to reverse inadvertent 
practice patterns? In our view, while Italian physicians 
and other authorities disseminate recommendations 
based on evidence, the present questionnaire should be 
followed by an in-depth global investigation of current 
practice patterns. If the present Italian data are represen-
tative of a widespread and mostly inappropriate use of Se, 
all our thyroid societies and their members have an obli-
gation to correct this and make it clear what the current 
recommendations are when facing our patients.
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